Toxicology Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Epidemiology, Faculty of Health, Ilam University Medical Sciences, Ilam, Iran.
BMC Infect Dis. 2023 Aug 19;23(1):543. doi: 10.1186/s12879-023-08504-5.
Helicobacter pylori is a gastrointestinal pathogen that infects around half of the world's population. H. pylori infection is the most severe known risk factor for gastric cancer (GC), which is the second highest cause of cancer-related deaths globally. We conducted a systematic review and meta-analysis to assess the global prevalence of GC in H. pylori-infected individuals.
We performed a systematic search of the PubMed, Web of Science, and Embase databases for studies of the prevalence of GC in H. pylori-infected individuals published from 1 January 2011 to 20 April 2021. Metaprop package were used to calculate the pooled prevalence with 95% confidence interval. Random-effects model was applied to estimate the pooled prevalence. We also quantified it with the I index. Based on the Higgins classification approach, I values above 0.7 were determined as high heterogeneity.
Among 17,438 reports screened, we assessed 1053 full-text articles for eligibility; 149 were included in the final analysis, comprising data from 32 countries. The highest and lowest prevalence was observed in America (pooled prevalence: 18.06%; 95% CI: 16.48 - 19.63; I: 98.84%) and Africa (pooled prevalence: 9.52%; 95% CI: 5.92 - 13.12; I: 88.39%). Among individual countries, Japan had the highest pooled prevalence of GC in H. pylori positive patients (Prevalence: 90.90%:95% CI: 83.61-95.14), whereas Sweden had the lowest prevalence (Prevalence: 0.07%; 95% CI: 0.06-0.09). The highest and lowest prevalence was observed in prospective case series (pooled prevalence: 23.13%; 95% CI: 20.41 - 25.85; I2: 97.70%) and retrospective cohort (pooled prevalence: 1.17%; 95% CI: 0.55 - 1.78; I 2: 0.10%).
H. pylori infection in GC patients varied between regions in this systematic review and meta-analysis. We observed that large amounts of GCs in developed countries are associated with H. pylori. Using these data, regional initiatives can be taken to prevent and eradicate H. pylori worldwide, thus reducing its complications.
幽门螺杆菌是一种胃肠道病原体,感染了全球约一半的人口。幽门螺杆菌感染是已知的导致胃癌(GC)的最严重风险因素,胃癌是全球癌症相关死亡的第二大原因。我们进行了一项系统评价和荟萃分析,以评估全球幽门螺杆菌感染人群中 GC 的患病率。
我们对 2021 年 1 月 1 日至 2021 年 4 月 20 日期间发表的关于幽门螺杆菌感染个体中 GC 患病率的研究进行了系统的 PubMed、Web of Science 和 Embase 数据库检索。使用 Metaprop 软件包计算 95%置信区间的汇总患病率。应用随机效应模型估计汇总患病率。我们还用 I 指数进行了量化。根据 Higgins 分类方法,I 值高于 0.7 被确定为高度异质性。
在筛选出的 17438 份报告中,我们评估了 1053 篇全文文章的纳入资格;最终分析纳入了 149 篇文章,这些文章来自 32 个国家。观察到最高和最低的患病率分别在美国(汇总患病率:18.06%;95%CI:16.48-19.63;I:98.84%)和非洲(汇总患病率:9.52%;95%CI:5.92-13.12;I:88.39%)。在个别国家中,日本幽门螺杆菌阳性患者的 GC 汇总患病率最高(患病率:90.90%;95%CI:83.61-95.14),而瑞典的患病率最低(患病率:0.07%;95%CI:0.06-0.09)。在前瞻性病例系列研究(汇总患病率:23.13%;95%CI:20.41-25.85;I2:97.70%)和回顾性队列研究(汇总患病率:1.17%;95%CI:0.55-1.78;I2:0.10%)中观察到最高和最低的患病率。
在这项系统评价和荟萃分析中,幽门螺杆菌感染在 GC 患者中的分布在不同地区存在差异。我们观察到,发达国家中大量的 GC 与幽门螺杆菌有关。利用这些数据,可以在全球范围内采取区域性举措来预防和根除幽门螺杆菌,从而减少其并发症。